PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Sep 22, 2020
Sep 22, 2020

byprotokinetixp

dry-eye | Ocular inflammation

Dry eye disease (DED) is a multifactorial disease of the ocular surface which results in a spectrum of symptoms and/or signs that affect 5 30% of the population. Download our dry eye disease investors deck to learn how Protokinetix is creating biotechnology that can help change the future of how we treat dry eye disease.
Sep 21, 2020
A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including nearly twice as many women as men. There is no single cause for eye dryness. It can be temporary or chronic and result from a...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule